This website is intended for healthcare professionals only.

Hospital Healthcare Europe
Hospital Pharmacy Europe     Newsletter    Login            

Treatment with opiates and benzodiazepine increases mortality risk

While rates of opiate prescribing in the US has levelled off, it appears that co-prescription with benzodiazepines is on the increase.

Although long-term benzodiazepine use is associated with an increased mortality risk, whether this risk is greater when combined with opiates remains unclear.

Both insomnia and anxiety are often managed through prescription of benzodiazepines. However, these drugs are associated with several adverse effects including an increased the risk of falls, cognitive impairment and a life-threatening risk when being withdrawn. Though some evidence suggests that benzodiazepine use alone increases mortality risk and that co-prescription with opiates is also potentially lethal, the data is inconsistent.

Article continues below this sponsored advert
Cogora InRead Image
Explore the latest advances in respiratory care at events delivered by renowned experts from CofE

As a result, a team from the Health and Behaviour Research Centre, Department of Psychiatry, Washington University, US, turned to data available in the National Health and Nutrition Surveys (NHANES) to examine the association between benzodiazepine use, either alone or in combination with opiates and mortality. Using the NHANES data set collected between 1999 and 2104, researchers obtained a nationally representative sample of approximately 5000 participants for whom mortality data was available through to 2015. Eligible patients were 20 years and older and data on prescription use was also obtained from NHANES as were potential covariates for the analysis including other medical and psychiatric conditions which may have been associated with an increased risk of mortality. In addition, a cohort of patients prescribed selective serotonin re-uptake inhibitors (SSRIs) were included as a control group.

The sample contained 5212 participants (38.2% male) with a mean age of 54.8 years of whom, 468 (9%) were co-prescribed benzodiazepines and opiates, 1256 (24.1%) benzodiazepines alone and 1955 (37.5%) opiates alone. In addition, 1533 were prescribed neither benzodiazepines or opiates but SSRIs. After a median follow-up of 6.7 years, there were 101 deaths in those receiving co-treatment, 236 among benzodiazepine only and 227 deaths among SSRI users. After adjustment for covariates, there was a significant increased risk of death for co-treated individuals (hazard ratio, HR = 2.04, 95% CI 1.65 – 2.52) and although smaller, also a significant risk for those using benzodiazepines alone (HR = 1.60, 95% CI 1.33 – 1.92). Interestingly, the researchers observed a significant increased death risk for co-treatment only among those aged under 65 years of age (HR = 3.27, 95% CI 2.40 – 4.47) and among those taking benzodiazepines alone (HR = 1.81).

They concluded that co-treatment is associated with a twofold increased risk of mortality and called for a concerted effort among physicians and policy-makers to reduce prescribing of the medications and to identify those at an increased mortality risk.

Xu KY et al. Association between benzodiazepine use with or without opioid use and all-cause mortality in the United States, 1999-2015. JAMA Netw Open doi:10.1001/jamanetworkopen.2020.28557